Big Pharma Pressures Europe on Drug Pricing

Big pharma companies, including Eli Lilly and Pfizer, are facing increasing pushback from European governments over drug pricing. In response, they are employing a tactic that proved successful in the UK: threatening to pull investment plans to pressure policymakers.

Details

In the UK, drugmakers secured a win when the British government agreed to increase medicine spending as part of a broader deal to avoid U.S.-imposed tariffs. Now, the pressure has shifted to Germany, which is debating legislation to tighten spending on medicines.

Pfizer's CEO wrote a letter to the German chancellor warning that future investments in the country may be at risk due to proposed changes to pricing laws. Meanwhile, AstraZeneca warned it may not launch new medicines in Germany if these changes go ahead.

In June, Eli Lilly announced it would halve a planned $2.7 billion investment, also citing the proposed legislation.

Context

This standoff comes amid pressure from U.S. President Donald Trump to tie prescription medicine prices in the U.S. market to lower prices elsewhere, including Europe. Major drugmakers have struck deals with the White House to lower drug costs in exchange for tariff exemptions, adding to pressure for increasing prices in Europe.

What This Means for Investors

These developments highlight the growing tension between drugmakers and European governments over drug pricing. The outcomes could impact company profits and investment strategies in the region, making it important for investors to monitor regulatory changes closely.